Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414444 | 0.78 | IMPDH2 (0.44) | IMPDH2IMPDH1AURKATPX2AHR | |
| SCHEMBL3709074 | 0.77 | IMPDH2 (0.43) | IMPDH2IMPDH1AURKATPX2AHR | |
| SCHEMBL18552475 | 0.77 | IMPDH2 (0.43) | IMPDH2IMPDH1AURKATPX2AHR | |
| SCHEMBL5780953 | 0.77 | PRKCQ (0.46) | IMPDH2IMPDH1PRKCQPRKCD | |
| SCHEMBL2432305 | 0.73 | AR (0.43) | IMPDH2IMPDH1ARPRKCQPRKCD | |
| SCHEMBL31416308 | 0.73 | RHEB (0.50) | P2RX7AHRF7LTA4HF3 | |
| SCHEMBL830446 | 0.73 | RHEB (0.50) | P2RX7AHRF7LTA4HF3 | |
| SCHEMBL30309353 | 0.72 | IMPDH2 (0.57) | IMPDH2IMPDH1AHRMCL1RHEB | |
| SCHEMBL403956 | 0.72 | IMPDH2 (0.57) | IMPDH2IMPDH1AHRMCL1RHEB | |
| SCHEMBL1484655 | 0.72 | RHEB (0.46) | IMPDH2IMPDH1AURKATPX2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299457-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10710963-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| US-20190127326-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| US-10196353-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20170073309-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-9533948-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| EP-2875013-A1 | INDOLECARBONITRILES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2015-05-27 | — | — | EP | disclosed |
| US-20150080449-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-8957104-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| WO-2014013309-A1 | INDOLECARBONITRILES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-01-23 | — | — | WO | disclosed |
| US-20140024694-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property (No.2) Limit ed (GB) | 2014-01-23 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-10710963-B2 | Chemical compounds | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20140024694-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-11299457-B2 | Chemical compounds | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20150080449-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-10196353-B2 | Chemical compounds | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | IMPDH2 1830/4885IMPDH1 1196/4885AURKA 1124/4885 |
| US-20190127326-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
| US-20170073309-A1 | Chemical Compounds | AR, NR5A1, ESRRA | IMPDH2 3005/4885IMPDH1 3323/4885AURKA 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.